CN111388744A - Gel storage, preparation method thereof and application of gel storage in preparation of postoperative hemostatic preparation - Google Patents
Gel storage, preparation method thereof and application of gel storage in preparation of postoperative hemostatic preparation Download PDFInfo
- Publication number
- CN111388744A CN111388744A CN202010043831.2A CN202010043831A CN111388744A CN 111388744 A CN111388744 A CN 111388744A CN 202010043831 A CN202010043831 A CN 202010043831A CN 111388744 A CN111388744 A CN 111388744A
- Authority
- CN
- China
- Prior art keywords
- gel
- parts
- mass
- layer
- glyceride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0031—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Abstract
The invention relates to a gel storage, a preparation method thereof and application of the gel storage in preparation of a postoperative hemostatic preparation, and belongs to the technical field of biological medicines. The gel storage comprises 40-55 parts by mass of phospholipid, 40-55 parts by mass of glyceride and 5-20 parts by mass of cosolvent; or the outer layer gel reservoir is wrapped outside the inner layer gel reservoir; the outer layer gel storage comprises 28-38 parts by mass of phospholipid, 62-70 parts by mass of glyceride and 1-8 parts by mass of cosolvent, and the inner layer gel storage comprises 40-55 parts by mass of phospholipid, 40-55 parts by mass of glyceride and 5-20 parts by mass of cosolvent. Preferably, the gel reservoir further comprises a drug. The invention uses two raw materials of phospholipid and glyceride, and the gel precursor can be quickly gelatinized by meeting water through mixing, thereby quickly sealing bleeding points. The inner layer gel of the double-layer storage has the characteristics of quick gelation and high strength, the bleeding point is quickly sealed, the outer layer gel has strong adhesion, and the whole gel system is ensured not to easily fall off.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to a gel storage, a preparation method thereof and application of the gel storage in preparation of a postoperative hemostatic preparation.
Background
Bleeding is one of the most common manifestations after trauma occurs, but uncontrolled bleeding is considered to be a significant cause of death for the patient. The traditional hemostatic materials mainly comprise gauze, bandages, tourniquets and the like. However, conventional hemostasis is at the expense of blood supply to the distal tissue and is prone to complications.
Later, many new hemostatic materials have been developed, such as zeolites, sponges, polymeric materials, inorganic materials, nanomaterials, and the like. They each have a number of drawbacks. For example, zeolite materials generate heat during hemostasis, which may cause body damage. Inorganic materials are not metabolized well in the body, and the like.
Meanwhile, in many cases, the hemostatic material is required to have the property of rapid hemostasis without causing excessive blood loss. The gauze super-hydrophilic material can effectively stop bleeding, but often causes excessive blood loss. Many gel materials can directly seal the wound surface by utilizing the adhesive force of the materials, and are potential hemostatic materials. However, many gel materials are difficult to synthesize, have weak adhesion and are easy to fall off. Therefore, there is an urgent need to develop a good gel material suitable for hemostasis.
Disclosure of Invention
The invention solves the technical problems that the existing gel hemostatic material can not realize rapid hemostasis and has weak adhesion force to cause easy falling off, and provides a gel storage, which comprises 40-55 parts by mass of phospholipid, 40-55 parts by mass of glyceride and 5-20 parts by mass of cosolvent. The invention uses two raw materials of phospholipid and glyceride, and the gel precursor can be quickly gelatinized by meeting water through mixing, thereby quickly sealing bleeding points.
According to a first aspect of the present invention, there is provided a gel depot comprising 40 to 55 parts by mass of a phospholipid, 40 to 55 parts by mass of a glyceride and 5 to 20 parts by mass of a cosolvent.
Preferably, the gel reservoir further comprises a drug;
preferably, the drug is a hemostatic agent, an anti-inflammatory agent, or an analgesic.
Preferably, the phospholipid is soybean lecithin or egg yolk lecithin; the glyceride is diglyceride, triolein or cholesylglyceride; the cosolvent is absolute ethyl alcohol, methanol, propylene glycol or polyethylene glycol.
According to another aspect of the present invention, there is provided a gel reservoir comprising an outer layer of gel reservoir and an inner layer of gel reservoir, the outer layer of gel reservoir being wrapped around the outer portion of the inner layer of gel reservoir; the outer layer gel storage reservoir comprises 28-38 parts by mass of phospholipid, 62-70 parts by mass of glyceride and 1-8 parts by mass of cosolvent, and the inner layer gel storage reservoir comprises 40-55 parts by mass of phospholipid, 40-55 parts by mass of glyceride and 5-20 parts by mass of cosolvent.
Preferably, the outer layer gel reservoir and/or the inner layer gel reservoir further comprises a drug;
preferably, the drug is a hemostatic agent, an anti-inflammatory agent, or an analgesic.
According to another aspect of the present invention, there is provided a method of preparing a gel reservoir as described in any one of the above, comprising the steps of:
(1) mixing 40-55 parts by mass of phospholipid, 40-55 parts by mass of glyceride and 5-20 parts by mass of cosolvent to obtain a gel precursor;
(2) and (2) filling the gel precursor obtained in the step (1) into a syringe, and then pushing the gel precursor, wherein the gel precursor is gelatinized in water to obtain the gel storage.
Preferably, after the phospholipid, the glyceride and the cosolvent are mixed, the method further comprises the step of adding a medicament;
preferably, the drug is a hemostatic agent, an anti-inflammatory agent, or an analgesic.
According to another aspect of the present invention, there is provided a method of preparing a gel reservoir as described herein, comprising the steps of:
(1) mixing 28-38 parts by mass of phospholipid and 62-70 parts by mass of glyceride, adding 1-8 parts by mass of cosolvent to obtain an outer-layer gel precursor, adding 40-55 parts by mass of phospholipid and 40-55 parts by mass of glyceride, and adding 5-20 parts by mass of cosolvent to obtain an inner-layer gel precursor;
(2) respectively filling the outer-layer gel precursor and the inner-layer gel precursor obtained in the step (1) into a syringe of a double-syringe, then pushing the inner-layer gel precursor, gelling the inner-layer gel precursor with water to form inner-layer gel, and then pushing the outer-layer gel precursor to form outer-layer gel outside the inner-layer gel, thus obtaining the gel storage.
Preferably, in the preparation process of the outer layer gel precursor and/or the inner layer gel precursor, after the cosolvent is added, the method further comprises the step of adding a medicament;
preferably, the drug is a hemostatic agent, an anti-inflammatory agent, or an analgesic.
According to a further aspect of the present invention there is provided the use of any one of the gel depots for the preparation of a post-operative haemostatic preparation.
Generally, compared with the prior art, the above technical solution conceived by the present invention mainly has the following technical advantages:
(1) the invention uses two raw materials of phospholipid and glyceride, and the gel precursor can be quickly gelatinized by meeting water through mixing, thereby quickly sealing bleeding points.
(2) The gel depot of the present invention achieves rapid hemostasis without excessive blood loss, without sacrificing blood supply to the distal tissue, and without causing complications. The hemostatic process can not generate heat, can not cause the injury of the organism, and can be well metabolized and removed in vivo.
(3) According to the invention, preferably, the phospholipid and glyceride gel precursors with different proportions are prepared into double-layer gel for postoperative hemostasis; the gel precursor preparation with different properties adopts a double-barrel syringe to obtain the effect of a double-layer gel drug storage by injection, and the preparation can be quickly gelated when meeting water to play a role in stopping bleeding. The inner layer gel has the characteristics of quick gelation and high strength, can quickly seal bleeding points, has strong adhesion of the outer layer gel, and ensures that the whole gel system is not easy to fall off.
(4) The gel storage preferably also comprises medicines which can be hemostatic medicines, anti-inflammatory medicines or analgesics, can be used together with the hemostatic medicines to achieve a better hemostatic effect, can also be used together with the analgesics to relieve the pain of a patient through slow release medicines, and can be used together with the anti-inflammatory medicines to prevent inflammation and promote wound healing.
Drawings
FIG. 1 is a diagram of a single layer gel of the present invention.
FIG. 2 is a diagram of a bilayer gel of the present invention.
FIG. 3 illustrates the in vitro hemostasis process of the present invention.
FIG. 4 illustrates the in vivo hemostasis process of the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
Example 1
A gel storage used for postoperative hemostasis is prepared from 50 parts by weight of soybean lecithin, 50 parts by weight of glyceryl dioleate and 10 parts by weight of absolute ethyl alcohol, wherein the weight percentage is L G50/50.
The preparation steps are as follows:
s1: uniformly mixing 50 parts by mass of phospholipid, 50 parts by mass of glyceride and 10 parts by mass of cosolvent on a mixer to completely dissolve the phospholipid and the glyceride to obtain a gel precursor;
s2: the gel precursor obtained in step S1 is loaded into a syringe barrel of an injector, and then the gel precursor is pushed into water, and the gel precursor is gelled with water to form a gel, i.e., the gel storage is obtained, as shown in fig. 1.
Example 2
A gel storage used for postoperative hemostasis is prepared from the following raw materials, by weight, 40 parts of soybean lecithin, 40 parts of glyceryl dioleate and 5 parts of absolute ethyl alcohol, wherein the raw materials are recorded as L G40/40.
The preparation steps are as follows:
s1: uniformly mixing 40 parts by mass of phospholipid, 40 parts by mass of glyceride and 5 parts by mass of cosolvent on a mixer to completely dissolve the phospholipid and the glyceride to obtain a gel precursor;
s2: and (4) loading the gel precursor obtained in the step (S1) into a syringe barrel of an injector, and then pushing the gel precursor into water, wherein the gel precursor is gelatinized with water to form gel, namely the gel storage is obtained.
Example 3
A gel storage used for postoperative hemostasis is prepared from 55 parts by weight of soybean lecithin, 55 parts by weight of glyceryl dioleate and 20 parts by weight of absolute ethyl alcohol, wherein the weight percentage is L G55/55.
The preparation steps are as follows:
s1: uniformly mixing 55 parts by mass of phospholipid, 55 parts by mass of glyceride and 20 parts by mass of cosolvent on a mixer to completely dissolve the phospholipid and the glyceride to obtain a gel precursor;
s2: and (4) loading the gel precursor obtained in the step (S1) into a syringe barrel of an injector, and then pushing the gel precursor into water, wherein the gel precursor is gelatinized with water to form gel, namely the gel storage is obtained.
Example 4
A gel reservoir comprising an outer layer of gel reservoir and an inner layer of gel reservoir, the outer layer of gel reservoir being wrapped around the outer portion of the inner layer of gel reservoir; the outer layer gel storage reservoir comprises 35 parts by mass of phospholipid, 65 parts by mass of glyceride and 5 parts by mass of cosolvent, and the inner layer gel storage reservoir comprises 45 parts by mass of phospholipid, 45 parts by mass of glyceride and 10 parts by mass of cosolvent.
The preparation steps are as follows:
s1: mixing 35 parts by mass of phospholipid and 65 parts by mass of glyceride, adding 5 parts by mass of cosolvent to obtain an outer-layer gel precursor, and adding 45 parts by mass of phospholipid and 45 parts by mass of glyceride to 10 parts by mass of cosolvent to obtain an inner-layer gel precursor;
s2: respectively filling the outer layer gel precursor and the inner layer gel precursor obtained in the step (1) into a syringe barrel of a double-barrel syringe, then pushing the inner layer gel precursor into water, gelling the inner layer gel precursor with water to form inner layer gel, and then pushing the outer layer gel precursor to form outer layer gel outside the inner layer gel, namely obtaining the gel storage, as shown in fig. 2.
Example 5
A gel reservoir comprising an outer layer of gel reservoir and an inner layer of gel reservoir, the outer layer of gel reservoir being wrapped around the outer portion of the inner layer of gel reservoir; the outer layer gel storage comprises 28 parts by mass of phospholipid, 64 parts by mass of glyceride and 8 parts by mass of cosolvent, and the inner layer gel storage comprises 40 parts by mass of phospholipid, 55 parts by mass of glyceride and 5 parts by mass of cosolvent.
The preparation steps are as follows:
s1: mixing 28 parts by mass of phospholipid and 64 parts by mass of glyceride, adding 8 parts by mass of cosolvent to obtain an outer-layer gel precursor, and adding 40 parts by mass of phospholipid and 55 parts by mass of glyceride to 5 parts by mass of cosolvent to obtain an inner-layer gel precursor;
s2: respectively filling the outer-layer gel precursor and the inner-layer gel precursor obtained in the step (1) into a syringe barrel of a double-barrel syringe, then pushing the inner-layer gel precursor into water, gelling the inner-layer gel precursor with water to form inner-layer gel, and then pushing the outer-layer gel precursor to form outer-layer gel outside the inner-layer gel, thus obtaining the gel storage.
Example 6
A gel reservoir comprising an outer layer of gel reservoir and an inner layer of gel reservoir, the outer layer of gel reservoir being wrapped around the outer portion of the inner layer of gel reservoir; the outer layer gel storage reservoir comprises 37 parts by mass of phospholipid, 62 parts by mass of glyceride and 1 part by mass of cosolvent, and the inner layer gel storage reservoir comprises 52 parts by mass of phospholipid, 40 parts by mass of glyceride and 8 parts by mass of cosolvent.
The preparation steps are as follows:
s1: mixing 37 parts by mass of phospholipid and 62 parts by mass of glyceride, adding 1 part by mass of cosolvent to obtain an outer-layer gel precursor, and adding 52 parts by mass of phospholipid and 40 parts by mass of glyceride to 8 parts by mass of cosolvent to obtain an inner-layer gel precursor;
s2: respectively filling the outer-layer gel precursor and the inner-layer gel precursor obtained in the step (1) into a syringe barrel of a double-barrel syringe, then pushing the inner-layer gel precursor into water, gelling the inner-layer gel precursor with water to form inner-layer gel, and then pushing the outer-layer gel precursor to form outer-layer gel outside the inner-layer gel, thus obtaining the gel storage.
Example 7
The method comprises the steps of taking 100ul of fresh animal blood (the volume of the fresh animal blood is 10-15IU corresponding to 1ml of blood) containing 1% heparin sodium, adding the fresh animal blood into 12 penicillin bottles respectively, adding 300ul of L G of 35/65 into a L G35 group, adding 300ul of L1G of 50/50 into a L0G 50 group, adding 150ul of L4G precursor into a L2G 35+ L3G 50 group, turning one of the penicillin bottles of each group upside down respectively at 30s,2min and 5min, and taking a picture, wherein visible is that L G50 can stop most of blood at 30s, L G35+ L G50 also stops nearly half of the blood volume, L G35 also has a certain hemostatic effect, L G50 and L G35+ L G50 can basically stop the blood completely, L G35 stops most of the blood, 5G 35 can stop the blood completely at 5min, the three types of blood can be stopped completely, and the gel is not easy to fall off, and is not easy to fall off as shown in a picture.
Example 8
The method comprises the following steps of (1) anesthetizing a normal mouse to keep vital signs, taking out a part of liver of the mouse, and manufacturing a bleeding point by using a sharp instrument, (1) bleeding of the liver of the mouse to a certain degree after min, firstly injecting L G50/50 gel by using a double-barrel syringe, and rapidly closing the bleeding point by using the characteristic that the gel has the characteristics of rapid gelation and high strength, then immediately injecting L G35/65 gel, further closing the bleeding point, and ensuring that the gel has strong adhesion property and the whole gel system is not easy to fall off, (30 s-4min later, observing the bleeding condition of the mouse, and ensuring that the mouse does not bleed any more basically, then, removing the gel after injecting the gel for 4min, and thus, completely stopping bleeding of a wound, as shown in figure 4.
It will be understood by those skilled in the art that the foregoing is only a preferred embodiment of the present invention, and is not intended to limit the invention, and that any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (10)
1. A gel storage is characterized by comprising 40-55 parts by mass of phospholipid, 40-55 parts by mass of glyceride and 5-20 parts by mass of cosolvent.
2. A gel depot according to claim 1, further comprising a drug;
preferably, the drug is a hemostatic agent, an anti-inflammatory agent, or an analgesic.
3. A gel depot according to claim 1, wherein the phospholipid is soy lecithin or egg lecithin; the glyceride is diglyceride, triolein or cholesylglyceride; the cosolvent is absolute ethyl alcohol, methanol, propylene glycol or polyethylene glycol.
4. A gel reservoir comprising an outer layer of gel reservoir and an inner layer of gel reservoir, the outer layer of gel reservoir being wrapped around the outer portion of the inner layer of gel reservoir; the outer layer gel storage reservoir comprises 28-38 parts by mass of phospholipid, 62-70 parts by mass of glyceride and 1-8 parts by mass of cosolvent, and the inner layer gel storage reservoir comprises 40-55 parts by mass of phospholipid, 40-55 parts by mass of glyceride and 5-20 parts by mass of cosolvent.
5. A gel reservoir according to claim 4, wherein the outer layer and/or inner layer further comprises a drug;
preferably, the drug is a hemostatic agent, an anti-inflammatory agent, or an analgesic.
6. A method of preparing a gel reservoir according to any of claims 1 to 3, comprising the steps of:
(1) mixing 40-55 parts by mass of phospholipid, 40-55 parts by mass of glyceride and 5-20 parts by mass of cosolvent to obtain a gel precursor;
(2) and (2) filling the gel precursor obtained in the step (1) into a syringe, and then pushing the gel precursor, wherein the gel precursor is gelatinized in water to obtain the gel storage.
7. A method of preparing a gel depot according to claim 6, wherein the method further comprises the step of adding a drug after mixing the phospholipid, the glyceride and the cosolvent;
preferably, the drug is a hemostatic agent, an anti-inflammatory agent, or an analgesic.
8. A method of preparing a gel reservoir according to any of claims 4 to 5, comprising the steps of:
(1) mixing 28-38 parts by mass of phospholipid and 62-70 parts by mass of glyceride, adding 1-8 parts by mass of cosolvent to obtain an outer-layer gel precursor, adding 40-55 parts by mass of phospholipid and 40-55 parts by mass of glyceride, and adding 5-20 parts by mass of cosolvent to obtain an inner-layer gel precursor;
(2) respectively filling the outer-layer gel precursor and the inner-layer gel precursor obtained in the step (1) into a syringe of a double-syringe, then pushing the inner-layer gel precursor, gelling the inner-layer gel precursor with water to form inner-layer gel, and then pushing the outer-layer gel precursor to form outer-layer gel outside the inner-layer gel, thus obtaining the gel storage.
9. The method for preparing a gel depot according to claim 8, wherein the method further comprises the step of adding a drug after adding a cosolvent in the process of preparing the outer layer gel precursor and/or the inner layer gel precursor;
preferably, the drug is a hemostatic agent, an anti-inflammatory agent, or an analgesic.
10. Use of a gel depot according to any one of claims 1-5 for the preparation of a postoperative haemostatic preparation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010043831.2A CN111388744B (en) | 2020-01-15 | 2020-01-15 | Gel storage, preparation method thereof and application of gel storage in preparation of postoperative hemostatic preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010043831.2A CN111388744B (en) | 2020-01-15 | 2020-01-15 | Gel storage, preparation method thereof and application of gel storage in preparation of postoperative hemostatic preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111388744A true CN111388744A (en) | 2020-07-10 |
CN111388744B CN111388744B (en) | 2021-05-18 |
Family
ID=71412112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010043831.2A Active CN111388744B (en) | 2020-01-15 | 2020-01-15 | Gel storage, preparation method thereof and application of gel storage in preparation of postoperative hemostatic preparation |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111388744B (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
CN1220483C (en) * | 1998-05-11 | 2005-09-28 | 西巴特殊化学品控股有限公司 | Use of nanodispersions in pharmaceutical end formulations |
CN101014319A (en) * | 2004-06-04 | 2007-08-08 | 卡穆鲁斯公司 | Liquid depot formulation |
CN101027065A (en) * | 2004-06-15 | 2007-08-29 | 陈献 | Phospholipid compositions and methods for their preparation and use |
CN101541313A (en) * | 2006-10-05 | 2009-09-23 | 万能药生物有限公司 | Novel injectable depot compositions and process of preparation of such compositions |
CN102526753A (en) * | 2011-12-15 | 2012-07-04 | 成都师创生物医药科技有限公司 | In-situ phase change gel slow release system taking phospholipid as substrate and preparation method thereof |
CN102933200A (en) * | 2009-12-18 | 2013-02-13 | 莱迪杜德制药公司 | One-phase gel composition comprising phospholipids |
CN106924172A (en) * | 2017-03-10 | 2017-07-07 | 武汉百纳礼康生物制药有限公司 | A kind of huperzine lysotropic liquid crystal preparation and preparation method thereof |
CN109876193A (en) * | 2019-04-01 | 2019-06-14 | 西安交通大学 | A kind of two-layer compound paradental defect repair materials and preparation method thereof based on photocrosslinkable hydrogel |
-
2020
- 2020-01-15 CN CN202010043831.2A patent/CN111388744B/en active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1220483C (en) * | 1998-05-11 | 2005-09-28 | 西巴特殊化学品控股有限公司 | Use of nanodispersions in pharmaceutical end formulations |
US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
CN101014319A (en) * | 2004-06-04 | 2007-08-08 | 卡穆鲁斯公司 | Liquid depot formulation |
CN101027065A (en) * | 2004-06-15 | 2007-08-29 | 陈献 | Phospholipid compositions and methods for their preparation and use |
CN101541313A (en) * | 2006-10-05 | 2009-09-23 | 万能药生物有限公司 | Novel injectable depot compositions and process of preparation of such compositions |
CN102933200A (en) * | 2009-12-18 | 2013-02-13 | 莱迪杜德制药公司 | One-phase gel composition comprising phospholipids |
CN102526753A (en) * | 2011-12-15 | 2012-07-04 | 成都师创生物医药科技有限公司 | In-situ phase change gel slow release system taking phospholipid as substrate and preparation method thereof |
CN106924172A (en) * | 2017-03-10 | 2017-07-07 | 武汉百纳礼康生物制药有限公司 | A kind of huperzine lysotropic liquid crystal preparation and preparation method thereof |
CN109876193A (en) * | 2019-04-01 | 2019-06-14 | 西安交通大学 | A kind of two-layer compound paradental defect repair materials and preparation method thereof based on photocrosslinkable hydrogel |
Non-Patent Citations (3)
Title |
---|
周萌萌 等: "大豆卵磷脂/二油酸甘油酯溶致液晶的制备、表征及其作为醋酸奥曲肽载体的研究", 《中国医院药学杂志》 * |
周萌萌: "一种新型载药液晶凝胶***的研究", 《中国优秀硕士学位论文全文数据库》 * |
郭偲 等: "石杉碱甲前体液晶制剂的制备及释放度研究", 《中国新药杂志》 * |
Also Published As
Publication number | Publication date |
---|---|
CN111388744B (en) | 2021-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2351556A2 (en) | Encapsulated functional fine particle composition capable of spraying and preparation method thereof | |
AU2008346830B2 (en) | Mucosal tissue dressing and method of use | |
CN104888263B (en) | Biocompatible hemostatic prevents adhesion, promoting healing, the closed modified starch material of surgery | |
CN113248732B (en) | Preparation method of injectable self-adaptive natural hydrogel adhesive | |
KR20190004735A (en) | MEDICAL HYDROGEN GEL COMPOSITION, MEDICAL HYDRAULIC GEL, METHOD FOR PRODUCING THE SAME, AND USES | |
JP2020512107A (en) | Kit for pain reduction or treatment of incision site after surgery | |
BRPI9809725B1 (en) | composition and device for treating an injury | |
CN104717986A (en) | Hydrogel-forming material | |
CN101081308A (en) | Chitose haemostatic | |
CN103316377A (en) | Beta-cyclodextrin/carboxymethyl chitosan medical dressing and preparation method thereof | |
US8591940B2 (en) | Method of treating scar tissue | |
CA2647549A1 (en) | Bulking of soft tissue | |
CN108042840B (en) | Medical sponge | |
US20130022552A1 (en) | Blood clotting composition and method of use | |
CN111388744B (en) | Gel storage, preparation method thereof and application of gel storage in preparation of postoperative hemostatic preparation | |
CN114099936A (en) | Long-acting soluble microneedle for cosmetic filling and sustained-release administration and preparation method thereof | |
CN112791070B (en) | Anesthetic dressing and preparation method thereof | |
WO2000030578A1 (en) | Enzymatic treatment and prevention of hypertrophic skin | |
CN114177512A (en) | Layer-by-layer deposition antibacterial healing-promoting soluble microneedle patch and preparation method thereof | |
US7951393B2 (en) | Keloid therapy | |
CN104744723A (en) | Chitosan medical material, and preparation method and use thereof | |
CN115336410B (en) | Biological product DBT | |
US20210007903A1 (en) | Analgesic Nose Plugs | |
US20110290693A1 (en) | Abnormal Scar Therapy | |
McBride et al. | Successful treatment of a chronic facial abscess using a prolonged release antibiotic copolymer in a golden lion tamarin (Leontopithecus rosalia) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |